A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: metastaticcancertransplantationpatientsstem
  Phrases that lowered it: vaccinepharmacokineticsopen labelevaluatesingle
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 9.8% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 24.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.0% (raises risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Sponsor's past trials: 366 (lowers risk) · Sponsor's track record
• Design: sequential (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. NCT04642365 · started 2021 · scored riskier than 18% of active trials terminated
• A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors NCT02760797 · started 2016 · scored riskier than 12% of active trials completed
• A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors NCT04158583 · started 2019 · scored riskier than 18% of active trials terminated
• A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 NCT05867121 · started 2023 · scored riskier than 26% of active trials completed
• A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. NCT00773526 · started 2008 · scored riskier than 15% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.